Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05416333 · ClinicalTrials.gov registry record · Early Phase 1
Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA)
A Early Phase 1 study of Central Centrifugal Cicatricial Alopecia, sponsored by Wake Forest University Health Sciences.
- Active
- Registry status
- Early Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT05416333 is a Early Phase 1 study of Central Centrifugal Cicatricial Alopecia that is active but no longer recruiting, run by Wake Forest University Health Sciences. The registered enrollment target is 18 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05416333, a Early Phase 1 study of Central Centrifugal Cicatricial Alopecia, is active but no longer recruiting, sponsored by Wake Forest University Health Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this pilot study is to determine if azelaic acid shows potential to be an effective treatment for Central Centrifugal Cicatricial Alopecia (CCCA). In this study, the aim is to compare azelaic acid vs placebo since azelaic acid may increase anti-inflammatory effects that affect the hair growth cycle.
Conditions Studied
Interventions
- DRUG azelaic acid
- OTHER usual medication for CCCA
Study Locations (1)
North Carolina
- Wake Forest University Health Scieces - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2024-08-12 |
| Est. Completion | 2026-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05416333
The ClinicalTrials.gov registry entry for NCT05416333 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Central Centrifugal Cicatricial Alopecia appearing as the primary indexed condition, and to 2 interventions - of which azelaic acid is the first listed.
NCT05416333 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT05416333 about?
NCT05416333 is a clinical study titled "Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA)". The purpose of this pilot study is to determine if azelaic acid shows potential to be an effective treatment for Central Centrifugal Cicatricial Alopecia (CCCA). In this study, the aim is to compare azelaic acid vs placebo since azelaic acid may increase anti-inflammatory effects that affect the hai...
What is the current status of trial NCT05416333?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 18 participants. The study started on 2024-08-12. Estimated completion is 2026-12.
What conditions does trial NCT05416333 study?
This clinical trial studies the following conditions: Central Centrifugal Cicatricial Alopecia.
What interventions are being tested in trial NCT05416333?
The interventions under investigation include: azelaic acid (DRUG), usual medication for CCCA (OTHER).
Who is sponsoring clinical trial NCT05416333?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05416333 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Central Centrifugal Cicatricial Alopecia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.